With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.31886-58-5,(R)-(+)-N,N-Dimethyl-1-ferrocenylethylamine,as a common compound, the synthetic route is as follows.
Weigh I (5.0g, 19.4mmol) in 100mL reaction flask, dissolved with 50.0mL of ether, Sec-butyllithium (44.9 mL, 58.3 mmol, 1.3 M) was added dropwise to the reaction flask under nitrogen atmosphere, Stirred at room temperature for 2h, Weigh diphenylphosphine chloride (4.2mL, 23.3mmol) was added dropwise to the reaction flask, Warmed to reflux, 4h after the reaction is completed, The reaction solution was poured into water to quench, Extraction with ethyl acetate, drying, Ethyl acetate was removed by rotary evaporation, Purification by column chromatography on residue gave 7.5 g of the target compound VIII, Yield: 87.4%, yellow solid. Mass spectral analysis MALDI-TOF-MS m / z: 441 (M +).
As the paragraph descriping shows that 31886-58-5 is playing an increasingly important role.
Reference£º
Patent; Shanghai Maosheng Kanghui Technology Co., Ltd.; Jiang Xuefeng; Ying Yongcheng; Teng Haige; Chen Pei; (20 pag.)CN107286202; (2017); A;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis